In 14–3-3σ-deficient colorectal cancer cells treated with doxorubicin, Chk2 activation is reduced significantly compared with the wild-type cells, and Chk2 inhibition promotes the induction of mitotic catastrophe in wild-type cells [41]. This evidence concerns the gene CHEK2 and colorectal cancer.